Methylphenidate increases the motor effects of L-dopa in Parkinson's disease: A pilot study

Richard Camicioli, Eric Lea, John Nutt, Gary Sexton, Barry Oken

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

We determined whether methylphenidate, a dopamine transporter blocker, modifies motor, cognitive, or affective responses to L-Dopa in Parkinson's disease (PD). Five patients who reported benefit from L-Dopa/carbidopa and motor fluctuations were admitted and withdrawn from their usual antiparkinsonian medications. On 3 consecutive days in a randomized double-blinded fashion, they took 0.2 mg/kg oral methylphenidate or placebo followed 30 minutes later by a 1-hour intravenous L-Dopa (2 mg/kg per h) or placebo infusion. Vital signs, tapping, walking, dyskinesias, mood, anxiety, concentration, and arousal were monitored every 30 minutes. Cognitive testing was performed before and following the infusion. Methylphenidate combined with L-Dopa led to greater peak right-hand tapping speed than either alone. Dyskinesia severity increased most when methylphenidate and L-Dopa were co-administered. There were no differences between conditions on the Stroop test, digit ordering, simple reaction time, or covert orienting of attention validity effect. Methylphenidate alone led to improvement in choice reaction time. Change in self-assessed analogue ratings of mood, anxiety, arousal, or concentration did not differ between conditions. Methylphenidate increased the motor effects of L-Dopa with minimal effects on cognitive or affective functions, suggesting a physiologic role for the dopamine transporter in patients with PD with motor fluctuations.

Original languageEnglish (US)
Pages (from-to)208-213
Number of pages6
JournalClinical Neuropharmacology
Volume24
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Methylphenidate
Levodopa
Parkinson Disease
Dopamine Plasma Membrane Transport Proteins
Dyskinesias
Arousal
Reaction Time
Anxiety
Placebos
Carbidopa
Stroop Test
Antiparkinson Agents
Dopamine Antagonists
Vital Signs
Walking
Hand

Keywords

  • Dopamine transporter
  • L-Dopa
  • Methylphendidate
  • Parkinson's disease
  • Pharmacodynamics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Methylphenidate increases the motor effects of L-dopa in Parkinson's disease : A pilot study. / Camicioli, Richard; Lea, Eric; Nutt, John; Sexton, Gary; Oken, Barry.

In: Clinical Neuropharmacology, Vol. 24, No. 4, 2001, p. 208-213.

Research output: Contribution to journalArticle

@article{4f65b9778ff746c7897136ed97b7ac2f,
title = "Methylphenidate increases the motor effects of L-dopa in Parkinson's disease: A pilot study",
abstract = "We determined whether methylphenidate, a dopamine transporter blocker, modifies motor, cognitive, or affective responses to L-Dopa in Parkinson's disease (PD). Five patients who reported benefit from L-Dopa/carbidopa and motor fluctuations were admitted and withdrawn from their usual antiparkinsonian medications. On 3 consecutive days in a randomized double-blinded fashion, they took 0.2 mg/kg oral methylphenidate or placebo followed 30 minutes later by a 1-hour intravenous L-Dopa (2 mg/kg per h) or placebo infusion. Vital signs, tapping, walking, dyskinesias, mood, anxiety, concentration, and arousal were monitored every 30 minutes. Cognitive testing was performed before and following the infusion. Methylphenidate combined with L-Dopa led to greater peak right-hand tapping speed than either alone. Dyskinesia severity increased most when methylphenidate and L-Dopa were co-administered. There were no differences between conditions on the Stroop test, digit ordering, simple reaction time, or covert orienting of attention validity effect. Methylphenidate alone led to improvement in choice reaction time. Change in self-assessed analogue ratings of mood, anxiety, arousal, or concentration did not differ between conditions. Methylphenidate increased the motor effects of L-Dopa with minimal effects on cognitive or affective functions, suggesting a physiologic role for the dopamine transporter in patients with PD with motor fluctuations.",
keywords = "Dopamine transporter, L-Dopa, Methylphendidate, Parkinson's disease, Pharmacodynamics",
author = "Richard Camicioli and Eric Lea and John Nutt and Gary Sexton and Barry Oken",
year = "2001",
doi = "10.1097/00002826-200107000-00003",
language = "English (US)",
volume = "24",
pages = "208--213",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Methylphenidate increases the motor effects of L-dopa in Parkinson's disease

T2 - A pilot study

AU - Camicioli, Richard

AU - Lea, Eric

AU - Nutt, John

AU - Sexton, Gary

AU - Oken, Barry

PY - 2001

Y1 - 2001

N2 - We determined whether methylphenidate, a dopamine transporter blocker, modifies motor, cognitive, or affective responses to L-Dopa in Parkinson's disease (PD). Five patients who reported benefit from L-Dopa/carbidopa and motor fluctuations were admitted and withdrawn from their usual antiparkinsonian medications. On 3 consecutive days in a randomized double-blinded fashion, they took 0.2 mg/kg oral methylphenidate or placebo followed 30 minutes later by a 1-hour intravenous L-Dopa (2 mg/kg per h) or placebo infusion. Vital signs, tapping, walking, dyskinesias, mood, anxiety, concentration, and arousal were monitored every 30 minutes. Cognitive testing was performed before and following the infusion. Methylphenidate combined with L-Dopa led to greater peak right-hand tapping speed than either alone. Dyskinesia severity increased most when methylphenidate and L-Dopa were co-administered. There were no differences between conditions on the Stroop test, digit ordering, simple reaction time, or covert orienting of attention validity effect. Methylphenidate alone led to improvement in choice reaction time. Change in self-assessed analogue ratings of mood, anxiety, arousal, or concentration did not differ between conditions. Methylphenidate increased the motor effects of L-Dopa with minimal effects on cognitive or affective functions, suggesting a physiologic role for the dopamine transporter in patients with PD with motor fluctuations.

AB - We determined whether methylphenidate, a dopamine transporter blocker, modifies motor, cognitive, or affective responses to L-Dopa in Parkinson's disease (PD). Five patients who reported benefit from L-Dopa/carbidopa and motor fluctuations were admitted and withdrawn from their usual antiparkinsonian medications. On 3 consecutive days in a randomized double-blinded fashion, they took 0.2 mg/kg oral methylphenidate or placebo followed 30 minutes later by a 1-hour intravenous L-Dopa (2 mg/kg per h) or placebo infusion. Vital signs, tapping, walking, dyskinesias, mood, anxiety, concentration, and arousal were monitored every 30 minutes. Cognitive testing was performed before and following the infusion. Methylphenidate combined with L-Dopa led to greater peak right-hand tapping speed than either alone. Dyskinesia severity increased most when methylphenidate and L-Dopa were co-administered. There were no differences between conditions on the Stroop test, digit ordering, simple reaction time, or covert orienting of attention validity effect. Methylphenidate alone led to improvement in choice reaction time. Change in self-assessed analogue ratings of mood, anxiety, arousal, or concentration did not differ between conditions. Methylphenidate increased the motor effects of L-Dopa with minimal effects on cognitive or affective functions, suggesting a physiologic role for the dopamine transporter in patients with PD with motor fluctuations.

KW - Dopamine transporter

KW - L-Dopa

KW - Methylphendidate

KW - Parkinson's disease

KW - Pharmacodynamics

UR - http://www.scopus.com/inward/record.url?scp=0034903904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034903904&partnerID=8YFLogxK

U2 - 10.1097/00002826-200107000-00003

DO - 10.1097/00002826-200107000-00003

M3 - Article

C2 - 11479391

AN - SCOPUS:0034903904

VL - 24

SP - 208

EP - 213

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 4

ER -